Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Regents Of The University Of California (NPI 1184722779)

Field	Value
Entity Type	Organization
Organization	Regents Of The University Of California
Address	200 W Arbor Dr
City	San Diego
State	CA
ZIP	92103
Taxonomy	General Acute Care Hospital
NPI Enumerated	September 20, 2006

Payer Source	Total Paid
Medicaid	$264.9M
Medicare	$0

Key Findings

This provider reports no Medicare billing on file and instead derives $264.9M in lifetime revenue from Medicaid, making its footprint effectively single-payer (Medicaid) in the datasets available. The lack of Medicare revenue suggests analyses of payer mix, reimbursement exposure, and competitive benchmarking should focus on Medicaid dynamics rather than dual-payer comparisons.

Revenue is highly concentrated in a small set of high-cost oncology and radiation services: the precomputed top three Medicaid codes account for 36.6% of total Medicaid revenue, led by J9271 ($24.2M, 16.2%), 77386 ($19.8M, 13.3%), and J9299 ($10.4M, 7.0%). This concentration indicates that a few therapy lines—particularly checkpoint inhibitors and advanced radiation delivery—drive a disproportionate share of Medicaid dollars for this provider.

The code mix strongly indicates a hospital-based oncology and infusion center with integrated radiation and advanced diagnostic imaging services: high-revenue oncology drugs such as J9271, J9299, J9355, J9306, and J9035 appear alongside a top radiation delivery code 77386 and high-revenue imaging codes like 78815 and 71260. Together these codes—many with high per-claim payments—point to specialized cancer treatment capacity (systemic biologic therapies plus IMRT and PET/CT imaging) rather than a profile dominated by routine primary-care procedures.

Operational throughput is evident from very large claim counts across outpatient and diagnostic codes: examples include 0510 (206.1K claims, $7M revenue), G0463 (97.8K claims, $3.2M revenue), 80053 (244.5K claims, $2.7M revenue) and J3490 (127.9K claims, $2.8M revenue). These volumes, paired with the high-cost oncology items, suggest a busy hospital outpatient clinic and laboratory operation that processes large numbers of lower-dollar diagnostics alongside concentrated high-dollar infusions and procedures.

State-level competitive standing is dominant for multiple high-cost oncology and specialty codes: the provider ranks #1 in-state for 77386 (100th percentile), J9299 (100th percentile), J1745 (100th percentile), J2505 (100th percentile), J3380 (100th percentile), J9355 (100th percentile) and several others, and ranks #2 for J9271 (98th percentile). These rank and percentile positions indicate the provider is a major, often leading, statewide delivery point for complex oncology drugs and IMRT.

Several codes are flagged as statistical outliers relative to in-state peers, underscoring exceptional concentration in specific services: J9271 is described as an "extreme outlier, far above typical state volume," 71260 is also an "extreme outlier, far above typical state volume," and J3490 is likewise an "extreme outlier, far above typical state volume." Additionally, many oncology and imaging codes are labeled "notably above typical state volume," reinforcing that the provider’s service mix is unusually weighted toward these lines.

Financial and strategic sensitivity is concentrated in Medicaid policy and oncology reimbursement: because $264.9M is from Medicaid and top oncology/radiation codes account for 36.6% of that revenue, changes in Medicaid coverage, drug payment policies, or site-of-care reimbursement for IMRT and infusions could disproportionately affect this provider’s revenue profile. Contracting or programmatic shifts that impact coverage of high-cost injectables (e.g., J9271, J9299, J1745) or payment for 77386 should be prioritized in payer-provider negotiations and risk assessments.

The provider has a long tenure in the NPI file (enumerated 2006-09-20, ~20 years ago) and is listed under the General Acute Care Hospital taxonomy, which aligns with the observed service mix of hospital outpatient clinics, high-volume laboratory work, advanced imaging, oncology infusions, and radiation delivery. This established presence, together with statewide leadership on numerous specialty codes, supports the characterization of a mature, specialty-focused hospital provider in the California Medicaid market.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

890 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	6,240	$3,880	$24.2M
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	19,250	$1,030	$19.8M
J9299	Injection, nivolumab, 1 mg	4,000	$2,610	$10.4M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	2,280	$4,230	$9.6M
J2505	Injection, pegfilgrastim, 6 mg	2,000	$4,300	$8.6M
0510	N/A	206,120	$30	$7M
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	4,610	$1,480	$6.8M
J3380	Injection, vedolizumab, intravenous, 1 mg	3,710	$1,730	$6.4M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	1,540	$3,670	$5.6M
J9035	Injection, bevacizumab, 10 mg	2,550	$2,180	$5.6M

Showing 1–10 of 890

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.

Claims Volume vs. California Distribution

Regents Of The University Of California — 18 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. California median

890 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
81408	The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code.	8	10	380	$230	$10.8M
0450	N/A	137	450	16,140	$90	$3.6M
J9271	Injection, pembrolizumab, 1 mg	2	60	240	$4,460	$3.4M
J9299	Injection, nivolumab, 1 mg	1	20	810	$3,160	$3.1M
0681	N/A	6	10	40	$7,220	$2.4M
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	1	20	880	$600	$2.4M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3	10	1,000	$790	$1.8M
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	2	10	120	$3,650	$1.7M
81220	The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR…	14	110	190	$140	$1.6M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	2	10	220	$4,600	$1.5M

Showing 1–10 of 890

Nearby Providers

Other providers in the same ZIP code as Regents Of The University Of California, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Family Health Centers Of San Diego Inc	CA	Federally Qualified Health Center (FQHC)	$0	$95.2M
Scripps Health	CA	General Acute Care Hospital	$0	$64.2M
Ihs Radiology Medical Group, Inc.	CA	Diagnostic Radiology Physician	$0	$59.1M
New Alternatives, Inc.	CA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$32M
Mark Schechter	CA	Diagnostic Radiology Physician	$1.7M	$270
Harrison Wang	CA	Diagnostic Radiology Physician	$1.3M	$0
Scripps Mercy Ambulatory Surgery Center, LP	CA	Ambulatory Surgical Clinic/Center	$723.3K	$551.3K
Randy Fanous	CA	Diagnostic Radiology Physician	$339.6K	$911.3K
Michael Booker	CA	Diagnostic Radiology Physician	$1.2M	$0
William Freeman	CA	Ophthalmology Physician	$1.2M	$0

Regents Of The University Of California — Billing Profile & Reimbursement Data

Sign up for Regents Of The University Of California — Billing Profile & Reimbursement Data policy alerts

Regents Of The University Of California — Billing Profile & Reimbursement Data

Sign up for Regents Of The University Of California — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References